Annovis Bio Statistics
Share Statistics
Annovis Bio has 13.80M shares outstanding. The number of shares has increased by 27.2% in one year.
| Shares Outstanding | 13.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 16.85% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.98M |
| Failed to Deliver (FTD) Shares | 430 |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 1.40M, so 10.15% of the outstanding shares have been sold short.
| Short Interest | 1.40M |
| Short % of Shares Out | 10.15% |
| Short % of Float | 12.93% |
| Short Ratio (days to cover) | 4.4 |
Valuation Ratios
The PE ratio is -3 and the forward PE ratio is -4.17.
| PE Ratio | -3 |
| Forward PE | -4.17 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -21.77 |
| P/FCF Ratio | -4.22 |
| PEG Ratio | n/a |
Enterprise Valuation
Annovis Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.
| Current Ratio | 2.39 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 7.25% and return on capital (ROIC) is 581.03%.
| Return on Equity (ROE) | 7.25% |
| Return on Assets (ROA) | -5.51% |
| Return on Capital (ROIC) | 581.03% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -9.37M |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -51.74% in the last 52 weeks. The beta is 1.7, so Annovis Bio 's price volatility has been higher than the market average.
| Beta | 1.7 |
| 52-Week Price Change | -51.74% |
| 50-Day Moving Average | 7.71 |
| 200-Day Moving Average | 8.6 |
| Relative Strength Index (RSI) | 32.09 |
| Average Volume (20 Days) | 267.16K |
Income Statement
In the last 12 months, Annovis Bio had revenue of $0 and earned -$56.20M in profits. Earnings per share was $-6.23.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -45.04M |
| Net Income | -56.20M |
| EBITDA | -45.04M |
| EBIT | - |
| Earnings Per Share (EPS) | -6.23 |
Balance Sheet
The company has $5.75M in cash and $0 in debt, giving a net cash position of $5.75M.
| Cash & Cash Equivalents | 5.75M |
| Total Debt | 0 |
| Net Cash | 5.75M |
| Retained Earnings | -110.26M |
| Total Assets | 14.36M |
| Working Capital | 8.97M |
Cash Flow
In the last 12 months, operating cash flow was -$39.97M and capital expenditures $0, giving a free cash flow of -$39.97M.
| Operating Cash Flow | -39.97M |
| Capital Expenditures | 0 |
| Free Cash Flow | -39.97M |
| FCF Per Share | -4.43 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ANVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -118.44% |
| FCF Yield | -55.07% |
Analyst Forecast
The average price target for ANVS is $25, which is 375.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $25 |
| Price Target Difference | 375.3% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -18.8 |
| Piotroski F-Score | 0 |